Tag Archives: pharmaceutical development

Twitter Weekly Updates for 2010-07-25

  • Orphan protection and data exclusivity can be stronger than patent protection if your technology fits! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-07-18

  • Training packages to suite any timetable! Watch this space for how to commercialize a drug delivery system! #
  • Mhra meetings, getting thr right team, with right experise and right history with the regulators is critical! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-07-11

  • When choosing the lead compound for a drug delivery technology development programme its critical to take a measured commercial approach! #
  • RT @reuters: UPDATE 1-AstraZeneca agrees drug discovery tie-up with MRC http://bit.ly/cROBBE #
  • @andrew_ellis yeah ace film loved it, loved it loved it. in reply to andrew_ellis #
  • The MHRA will give a regulatory advice meeting without charge if the situation justifies it! This can add clarity to a project! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-07-04

  • Its my birthday today so the office is closed, but I have masses of updated info for you tomorrow! #
  • MHRA meetings can go quickly when you have the proposed plan well defined and justified, it makes you investor ready! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-06-27

  • Business plans need a clean structure that tells a story! #
  • Conventional wisdom is not always correct! Once again a great result at the drug regulators that flies in the face of conventional wisdom. #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-06-13

  • Wow the new site is realy driving traffic and loads of people are signing up for our regulatory watch service – ha…http://www.damienbove.com #
  • The boundary between traditional science and new-wave science in healthcare is shrinking and weakening. #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-06-06

  • ICHM3 consultancy services, new page launched! Check it out to access our world class pre-clinical expertise! #

Powered by Twitter Tools

Drug Regulators,FDA, Publish ICH Questions and Answers, Q8,Q9 and Q10

Drug Regulators,FDA, Publish ICH  Questions and Answers, Q8,Q9 and Q10

Full Text Here

Since the Q8, Q9, and Q10 guidances were made final, experiences implementing the guidances in the ICH regions have given rise to requests for clarification. This question and answer (Q&A) document is intended to clarify key issues. The guidance reflects the current working procedure of the ICH Quality Implementation Working Group (Q-IWG) for implementing the Q8, Q9, and Q10 guidances.
The benefits of harmonizing technical requirements across the ICH regions can be realized only if the various quality ICH guidances are implemented and interpreted in a consistent way across the three regions. The Q-IWG is tasked to develop Q&As to facilitate implementation of existing quality guidance.

Q8 (R2) Pharmaceutical Development (includes the Q8 parent guidance (Part I) and the annex (Part II), which provides further clarification of the Q8 parent guidance and describes the principles of quality by design)

Q9 Quality Risk Management

Q10 Pharmaceutical Quality Systems

Click Here for – Drug Development Services – Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulators,FDA, Publish ICH  Questions and Answers, Q8,Q9 and Q10

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulators,FDA, Publish ICH  Questions and Answers, Q8,Q9 and Q10

Twitter Weekly Updates for 2010-05-23

  • The smallest detail of your development plan needs to support any orphan indication claims! #
  • The best way to understand a process is to go through it, be that orphan, pediatric or herbal registration! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-05-09

  • When undertaking large projects with consultants its to fire and forget, you need to engage for the optimal result, its collaboration! #
  • MHRA are turning meeting requests around quickly at the moment! So its a good idea to have the documentation ready before making a request #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-04-11

  • Selling healthcare technologies into the NHS takes more than sales skills, it takes knowledge! We can help, US companies come to europe! #
  • Whilst its tempting to try and squeeze tons of efficacy data from a first in man study it does require careful management. #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-04-04

  • Expert panels are a hugely cost effective way of getting lots of high quality advice in drug development! Or due diligence! #
  • Test #
  • Expert opinions are massively valuable and an expert panel is a great cost effective way of accessing them, #
  • Test #
  • For many orphan indications there is a lack of reliable prevalence data, so conclusions can only be drawn from limited data, its confidence #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-03-28

  • Consultancy outcomes should be consistent with the terms of insurance! Ask to see insurance certs when buying services! #
  • Regulatory advice, sometimes its a few short questions, but it can be a huge answer! #
  • Lots of new training opportunities will be comming out in next few months! Keep those eyes peeled to our newsletter! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-03-21

  • Business planning for healthcare technologies is all about telling a story! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-03-14

  • When you have to guess, and educated guess carries much more weight than an uneducated one! #
  • Don't underestimate the beauty of electronic document submission! Just printed and posted an FDA orphan application, heavy!!! #
  • I just updated my Squidoo page: First In Man Clinical Trials Regulations course http://tinyurl.com/yfp8l5o #
  • Regulation of first in man clinical trails course open for bookings! Still only £500, http://www.damienbove.com/course #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-03-07

  • Some projects require a huge amount of work to develop a scope! This requires a professional and flexable approach! #
  • Contemplation is as powerful as action! However like all powerful flavours it needs to be used in careful moderation! #
  • When you biomarker is a hormone or steroid you realy need to understand its circadian rhythm, measuring at the wrong time can ruin your data #
  • an FDA orphan application, realy taxes a tree! But this weighty document will add value to you IP! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-02-28

  • A comprahensive training package for those involved in healthcare technology commercialisation will be launched soon watch this space #
  • When thinking about medical devices marketing is so much more important than with drugs! Route to market needs to be in you development plan #
  • New business support website to be launched soon! Helping consultants profit maximise! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-02-21

  • Choice of regulator for scientific advice is not as simple as it looks! Agencies that approve you CTA might not do you marketing license! #
  • Flexibility is key when dealing with regulators! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-02-14

  • Licensing can be simple when you proposition is simple and the technology is a fit with current activites, without that its challenging #
  • Keeping ontop of admin can be damed demanding but all too esential, its like taking time to learn new things! #
  • Herbal medicines are a very important part of the medicine cabinet! Our experts can get yours to market with minimal fuss and expense! #
  • Framework programmes require some signigicant investment of time and experise in order to acheive success! You need the right team! #

Powered by Twitter Tools

Twitter Weekly Updates for 2010-02-07

  • Whilst a methodical process is esential, sometimes asking an expert for a gut feel can slash months of time and expense from a project! #
  • Opportunities come along that give you a chance to share your expertise with a huge number of people! Take them and run with it. #
  • New FDA non clinical guidlines! Video review available later today! Go to http://www.damienbove.com and click on reports! #
  • Development can take longer than expected, discovery more so than development, but don't make the error or not having a plan! #

Powered by Twitter Tools